Skip to Content

TEVA 2050 TEVA 2050 (Tolterodine Tartrate Extended-Release 2 mg)

Pill with imprint TEVA 2050 TEVA 2050 is Green, Capsule-shape and has been identified as Tolterodine Tartrate Extended-Release 2 mg. It is supplied by Teva Pharmaceuticals USA Inc..

Tolterodine is used in the treatment of urinary frequency; urinary incontinence and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. Tolterodine 2 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for TEVA 2050 TEVA 2050

Tolterodine tartrate extended-release 2 mg TEVA 2050 TEVA 2050
Tolterodine tartrate extended-release 2 mg TEVA 2050 TEVA 2050
Tolterodine tartrate extended-release 2 mg TEVA 2050 TEVA 2050
Tolterodine tartrate extended-release 2 mg TEVA 2050 TEVA 2050

Tolterodine Tartrate Extended-Release

Imprint
TEVA 2050 TEVA 2050
Strength
2 mg
Color
Green
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Urinary antispasmodics
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Teva Pharmaceuticals USA Inc.
National Drug Code (NDC)
00093-2050

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.